MONALEESA-3: Quality of Life Analysis
Strategic Insight: While CDK4/6 inhibitors add toxicity, this analysis confirms that Ribociclib + Fulvestrant maintains Quality of Life (QoL) compared to placebo, while significantly extending progression-free survival. The data reveals a "Risk Paradox": despite more adverse events, the time to definitive deterioration in health status is delayed.
"Adding ribociclib to fulvestrant maintains HRQOL... delaying deterioration in HRQOL in this trial should be considered an important result."
Study Context
N = 726 Postmenopausal HR+/HER2-
Design: Randomized 2:1 (Ribo vs Placebo)
Follow-up: Median 20.4 months
Study Design & Population Structure
Baseline Comparability: QoL & Symptoms
Ribociclib
Placebo
Scores (0-100). Higher Global Health is better; Lower Symptom score is better. Groups were balanced at baseline.
Risk of Deterioration (Hazard Ratios)
HR < 1.0 favors Ribociclib (Slower deterioration). Error bars = 95% CI.
Delaying Deterioration: Physical Functioning
Mean months to ≥10% deterioration (M05). Ribociclib extends time to decline by ~3.8 months.
Pain Severity Index: Risk Reduction
Outcome Summary Matrix
Data Appendix
| Metric | Group | Value | Notes |
|---|
Source: | DOI: